Last reviewed · How we verify
Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOP).
Details
| Lead sponsor | Alcon Research |
|---|---|
| Phase | Phase 4 |
| Status | TERMINATED |
| Enrolment | 37 |
| Start date | 2012-06 |
| Completion | 2013-11 |
Conditions
- Glaucoma
Interventions
- Travoprost/Timolol Maleate BAK-Free Fixed Combination
Primary outcomes
- Change in intra-ocular pressure (IOP) at final visit from prior therapy (i.e., from baseline) — 12 weeks
Goldmann applanation tonometry will be performed at the baseline visit and the 12-week visit to record IOP. Change in IOP will be calculated. IOP will be measured in mmHg.
Countries
Brazil